




RealRate

PHARMACEUTICAL 2018

Arbutus Biopharma Corp
Rank 131 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is -97%, being 180% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	129,366
Cost of Goods Sold	0
Intangible Assets	83,011
Liabilities, Current	14,627
Liabilities, Non-Current	0
Other Assets	12,601
Other Compr. Net Income	0
Other Expenses	18,505
Other Liabilities	40,061
Other Net Income	2,197
Property and Equipment	12,183
Research and Development	62,676
Revenues	10,700
Selling, General and Administrative Expense	16,129

Output Variable	Value in 1000 USD
Assets	237,161
Liabilities	54,688
Expenses	97,310
Stockholders Equity	182,473
Net Income	-84,413
Comprehensive Net Income	-84,413
Economic Capital Ratio	-97%